Abstract 1853P
Background
Frankl's Logotherapy is a psychotherapeutic approach aimed at finding meaning in life. Although the incidence of death anxiety, existential loneliness, and depression in cancer patients is high, the efficacy of Logotherapy in this population is not well established.
Methods
Two independent investigators searched PubMed, Embase, and Cochrane Library databases up to March 2023. We systematically reviewed, according to PRISMA guidelines, controlled clinical trials evaluating the use of Logotherapy in cancer anxiety symptoms. We performed a pooled analysis on anxiety scores of patients that underwent group Logotherapy sessions vs. non-exposed control groups.
Results
We included seven studies, four randomized controlled trials (RCTs), and three quasi-experimental, comprising 280 patients, published between 1977 and 2023. A total of 139 patients (49.6%) had sessions of Logotherapy, and ages ranged from 18 to more than 68 years. Total treatment duration ranged between 360 and 1200 minutes. The Standard Mean Difference (SMD) for anxiety symptoms was -1.63 (95% CI = [-2.65, -0.61]; z = 3.12; P = 0.002; I2 = 92%) in patients who underwent Logotherapy compared to non-exposed control groups. In a subgroup analysis including only RCTs, a similar effect was observed with an SMD of -0.64 (95% CI = [-1.72, 0.44]; z = 1.16; P = 0.25; I2 = 91%).
Conclusions
Despite limited evidence, Logotherapy group sessions were associated with a reduction in anxiety scores of adult patients with cancer when compared to inactive control groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.V. Teixeira Filho.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05